Target intelligence / Profile preview

Actin gamma 2, smooth muscle (ACTG2)

Target
ACTG2
Molecular classification
Other (cytoskeletal protein), actin family
01

Overview

Actin gamma 2, smooth muscle (ACTG2) is a member of the actin family of highly conserved cytoskeletal proteins. Specifically, ACTG2 encodes the smooth muscle–specific γ2 actin isoform that is critical for the formation and function of contractile filaments in enteric and visceral smooth muscle cells, such as those of the gastrointestinal and urinary tracts[1][2][3][4][6]. This protein is essential for the contraction required to move food through the intestines and expel urine from the bladder[1][2][3]. Mutations in ACTG2 disrupt filament polymerization, resulting in impaired muscle contractility and visceral myopathies like MMIHS and familial visceral myopathy, which present as severe GI and urinary dysmotility[1][3][5][7]. ACTG2 is not a drug target, but its variant status can serve as a diagnostic biomarker for visceral myopathies[5].

Other names
ACTACTA3ACTEACTL3ACTSGVSCMactingamma-enteric smooth muscle isoform 1 precursorgamma-enteric smooth muscle isoform 2 precursoractin-like proteinalpha-actin-3
02

Mechanism of action

Not applicable; no drugs directly target ACTG2

03

Biological functions

Smooth muscle contractionCytoskeleton maintenanceCell motility
04

Disease associations

Visceral myopathy (including familial visceral myopathy)Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS)Intestinal pseudo-obstructionIntestinal malrotationPossibly small intestinal neuroendocrine tumorigenesisUrinary tract dysfunction and recurrent infections
05

Safety considerations

No established safety concerns; gene mutations lead to intrinsic smooth muscle dysfunction rather than representing a druggable risk
06

Interacting drugs

None with direct, clinically validated interaction (ACTG2 is not a standard therapeutic target for approved drugs)
07

Biomarkers

ACTG2 mutation status for diagnosis/prognosis in visceral myopathy/MMIHS

Beyond the preview

Go deeper on Actin gamma 2, smooth muscle (ACTG2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actin gamma 2, smooth muscle (ACTG2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call